Why Is LIQUIDIA CORP (LQDA) Stock Down Today?

LQDA stock fell 10.02% to $79.23 in Monday trading, marking one of the largest declines in recent days. The drop came despite the company reporting a significant revenue beat in its second-quarter results. The stock opened with a -3.5% gap and traded lower throughout the session, reaching an intraday low of $79.00. The sell-off appears to be driven by a combination of earnings estimates not meeting expectations and a wave of insider selling.

What Happened

Liquidia reported second-quarter net product sales of $170.4 million, a dramatic increase from $6.5 million in the same period last year, driven by strong adoption of its inhaled treprostinil product, YUTREPIA. The company also noted progress in its clinical pipeline and growing market share in the inhaled prostacyclin space, with YUTREPIA now capturing approximately 30% of the market. However, the stock declined after the earnings report, as investors reacted to an earnings per share (EPS) result that fell short of expectations. The company’s CEO, Roger Jeffs, highlighted growing demand for the drug during the earnings call, but the stock moved lower as analysts and investors assessed the broader picture.

The stock’s decline also coincided with a series of insider transactions. Chief Business Officer Jason Adair, Chief Accounting Officer Dana Boyle, and Director Stephen M. Bloch all sold shares in the past week. These sales, totaling $140.6 million in the last 90 days, may have contributed to investor uncertainty. Additionally, Bank of America Securities downgraded the stock to Neutral and raised its price target to $79, while HC Wainwright & Co. maintained a Buy rating with a $130 price target.

What The Data Shows

The stock opened at $84.93 and fell steadily through the session, with volume reaching 1.8 million shares, 1.0x the 3-month average. The 52-week range is $19.90 to $93.61, and the stock is currently trading near the lower end of that range. Liquidia’s fundamentals show a market cap of $8.0 billion, a P/E ratio of 379.3, and trailing twelve-month revenue growth of 1936.7%. Despite a net margin of 7.7%, the stock’s high valuation and recent insider selling may be weighing on investor sentiment.

What To Watch

The stock is set to remain under pressure as investors monitor the company’s ability to meet its $1 billion net revenue goal for 2027. Coverage of the stock has increased in the past 36 hours, with 13 stories from nine sources. Analyst ratings and further insider activity will be key to watch in the coming weeks.